SRR1387989
GTEX
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- GTEX
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- GTEX
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- IL6_JAK_STAT3_SIGNALING+0.507
- INFLAMMATORY_RESPONSE+0.462
- TNFA_SIGNALING_VIA_NFKB+0.461
- CHOLESTEROL_HOMEOSTASIS+0.458
- ALLOGRAFT_REJECTION+0.455
- ANGIOGENESIS+0.412
- COAGULATION+0.366
- IL2_STAT5_SIGNALING+0.360
- INTERFERON_GAMMA_RESPONSE+0.334
- COMPLEMENT+0.310
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.544
- DNA_REPAIR-0.345
- HEDGEHOG_SIGNALING-0.341
- MYC_TARGETS_V2-0.297
- NOTCH_SIGNALING-0.296
- MYC_TARGETS_V1-0.228
- ADIPOGENESIS-0.197
- UV_RESPONSE_DN-0.193
- E2F_TARGETS-0.188
- UNFOLDED_PROTEIN_RESPONSE-0.147
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1468403 | GTEX | — | 0.957 |
| 2 | SRR1325401 | GTEX | — | 0.950 |
| 3 | SRR615731 | GTEX | — | 0.947 |
| 4 | SRR1079168 | GTEX | — | 0.939 |
| 5 | SRR1368856 | GTEX | — | 0.939 |
| 6 | SRR819534 | GTEX | — | 0.929 |
| 7 | SRR1441701 | GTEX | — | 0.916 |
| 8 | SRR1464411 | GTEX | — | 0.915 |
| 9 | SRR1073755 | GTEX | — | 0.911 |
| 10 | SRR661723 | GTEX | — | 0.906 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 31 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| IL6_JAK_STAT3_SIGNALING | 0.507 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.462 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.461 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.458 | Remibrutinib | — uncovered |
| ALLOGRAFT_REJECTION | 0.455 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.412 | Remibrutinib | — uncovered |
| COAGULATION | 0.366 | Binimetinib | — uncovered |
| IL2_STAT5_SIGNALING | 0.360 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.334 | Idelalisib | — uncovered |
| COMPLEMENT | 0.310 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.293 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.281 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.256 | Inavolisib | — uncovered |
| APOPTOSIS | 0.242 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.235 | Inavolisib | — uncovered |
| MYOGENESIS | 0.229 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.164 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.158 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.150 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.138 | Inavolisib | — uncovered |